Edwards Lifesciences's Corporate Customers have recorded an increase in their cost of revenue by 14.38 % in the 2 quarter 2026 year on year, sequentially costs of revenue grew by 17.61 %. During the corresponding time, Edwards Lifesciences Corporation recorded a revenue increase by 13.66 % year on year, sequentially revenue grew by 5.64 %. While revenue at the Edwards Lifesciences Corporation's corporate clients recorded rose by 6.14 % year on year, sequentially revenue grew by 4.54 %.
Edwards Lifesciences's Customers have recorded an increase in their cost of revenue by 14.38 % in the 2 quarter 2026 year on year, sequentially costs of revenue grew by 17.61 %, for the same period Edwards Lifesciences Corporation recorded revenue increase by 13.66 % year on year, sequentially revenue grew by 5.64 %.
Edwards Lifesciences's Comment on Sales, Marketing and Customers
The company operates in the cardiovascular segment of the medical technology industry, specializing in products and technologies aimed at improving clinical outcomes and demonstrating value. Its key market segments include structural heart disease treatment, with product lines in transcatheter aortic valve replacement (TAVR), transcatheter mitral and tricuspid therapies (TMTT), and surgical categories. Primary competitors are Medtronic plc and Abbott Laboratories. The company's customers comprise physicians, hospital executives, service line leaders, nursing and clinical staff, material managers, biomedical staff, hospital administrators, purchasing managers, and ministries of health. Sales are conducted through direct sales forces and independent distributors worldwide, with 58% of net sales projected in the United States and 42% internationally in 2025, including Europe, Japan, and other regions. The company also collaborates with hospital group purchasing organizations and national and regional buying groups, such as healthcare systems and Integrated Delivery Networks. Additionally, it provides educational symposia and training to support optimized patient outcomes.
News about Edwards Lifesciences Corporation Contracts
In an era marked by remarkable advancements in cardiac care, two recent announcements from Edwards Lifesciences highlight significant strides in valve technology aimed at enhancing the quality of life for patients with heart conditions. The company s commitment to innovation has led to compelling data that not only solidifies its industry leadership but also sheds light on gender-specific outcomes of heart valve procedures, particularly for women. Eight-Year Data on RESILIA Tissue Technology: A Leap Forward in DurabilityEdwards Lifesciences recently unveiled groundbreaking eight-year data confirming the long-term durability of its proprietary RESILIA tissue technology, which is used in aortic surgical valves...
In a striking turn of events, Edwards Lifesciences Corporation (NYSE: EW) is facing a class action lawsuit as investors react to a staggering market capitalization loss amounting to $16 billion. The prominent medical technology firm, renowned for its innovative heart valve therapies and critical care solutions, has recently reported concerning financial results that have prompted legal scrutiny and fallen stock prices.The foundation of this legal challenge lies in the company’s disappointing third-quarter performance, where it registered a notable decline in revenue a staggering 8.58% year-on-year, with a sequential drop of 2.32%. This decline is seemingly symptomatic of broader issues permeating Edwardsâ€...
Sophisticated Five-Year Study Shows Positive Outcomes for Female and Small Annulus Patients in Edwards TAVR Trials, Despite Economic ConcernsEdwards Lifesciences recently released findings from a comprehensive analysis of data collected over a five-year period as part of the PARTNER Trials. The study focused on transcatheter aortic valve replacement (TAVR) patients with a small annulus, and the results revealed excellent clinical outcomes and valve durability, regardless of the patients annulus size or sex. This groundbreaking research brings hope to individuals who may previously have had limited treatment options due to their unique anatomical considerations.The study included over 1,300 low and intermed...
Edwards Lifesciences’s Comment on Sales, Marketing and Customers
The company operates in the cardiovascular segment of the medical technology industry, specializing in products and technologies aimed at improving clinical outcomes and demonstrating value. Its key market segments include structural heart disease treatment, with product lines in transcatheter aortic valve replacement (TAVR), transcatheter mitral and tricuspid therapies (TMTT), and surgical categories. Primary competitors are Medtronic plc and Abbott Laboratories. The company's customers comprise physicians, hospital executives, service line leaders, nursing and clinical staff, material managers, biomedical staff, hospital administrators, purchasing managers, and ministries of health. Sales are conducted through direct sales forces and independent distributors worldwide, with 58% of net sales projected in the United States and 42% internationally in 2025, including Europe, Japan, and other regions. The company also collaborates with hospital group purchasing organizations and national and regional buying groups, such as healthcare systems and Integrated Delivery Networks. Additionally, it provides educational symposia and training to support optimized patient outcomes.
Sources:
Edwards Lifesciences Corporation’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Edwards Lifesciences Corporation’s corporate clients.
For your research, we’ve provided 9 tables on Edwards Lifesciences Corporation corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
111.49 %
6.14 %